Double-digit growth in its proton therapy and dosimetry business segments elevated proton therapy developer Ion Beam Applications (IBA) to greater revenues in the company's first quarter (end-March 31).
Revenues increased 27% to 58.6 million euros ($73.8 million U.S.), compared with
46.3 million euros ($58.3 million U.S.) in the first quarter of 2014.
Backlog in the company's proton therapy and other accelerators segments continues to reach new heights of 278.8 million euros ($351.3 million U.S.) at the end of the first quarter, the company reported.
